Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments

确立了雅培在快速增长的癌症筛查和诊断领域的领导地位

Advances Abbott's mission to make healthcare more accessible and give people more control over their health

推进Abbott的使命，使医疗保健更加普及，并让人们更好地掌控自己的健康。

ABBOTT PARK

雅培公园

, Ill.

，病态。

,

，

March 23, 2026

2026年3月23日

/

/

PRNewswire

美通社

/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people.

/ -- 雅培公司（Abbott，纽约证券交易所代码：ABT）今天宣布已完成对精密科学公司（Exact Sciences）的收购，此举使雅培成为快速增长的癌症筛查和诊断领域的领导者，并使公司能够为数百万人提供服务。

'Abbott's global scale, track record of operational and commercial excellence and work with healthcare systems around the world will expand access to important tools for early cancer detection and personalized treatments,' said

“雅培的全球规模、运营和商业卓越的记录，以及与世界各地医疗系统的合作，将扩大获取重要工具的机会，用于癌症的早期检测和个性化治疗，”

Robert B. Ford

罗伯特·B·福特

, chairman and chief executive officer, Abbott. 'With the legacy and deep expertise of the Exact Sciences team, we're ready to transform cancer care.'

，雅培公司董事长兼首席执行官。“凭借Exact Sciences团队的传承和深厚的专业知识，我们已准备好改变癌症治疗。”

Pursuant to the terms of the merger agreement, upon completion of the acquisition, Exact Sciences became a wholly owned subsidiary of Abbott. As a result of the completion of the acquisition, March 20, 2026, was the last day of trading of Exact Sciences shares on the Nasdaq Stock Market.

根据合并协议的条款，在收购完成后，Exact Sciences 成为了 Abbott 的全资子公司。由于收购的完成，2026 年 3 月 20 日是 Exact Sciences 股票在纳斯达克股票市场交易的最后一天。

Strategic fit

战略契合

The transaction positions Abbott to advance diagnostics that are more preventative, predictive and personalized while expanding the company's presence in one of the fastest-growing areas of healthcare as global cancer incidence continues to rise. It also adds a new growth vertical to Abbott's already high-single-digit growth expectations, establishing leadership in the fast-growing .

该交易使雅培能够推进更具预防性、预测性和个性化的诊断技术，同时在全球癌症发病率持续上升的情况下，扩大公司在医疗保健领域增长最快的业务之一的影响力。这也为雅培已经预期的高个位数增长增添了新的增长方向，确立了在快速发展的市场中的领导地位。

$60 billion

600亿美元

U.S. cancer screening and precision oncology diagnostics segments.

美国癌症筛查和精准肿瘤诊断领域。

Industry-leading offerings and pipeline

行业领先的产品和服务管道

Abbott now has a comprehensive suite of products and differentiated pipeline focused on the early detection of cancer and supporting personalized treatments. This includes the Cologuard® test, a market-leading noninvasive colorectal cancer screening option; Oncotype DX®, which informs personalized treatment decisions for patients with early-stage breast cancer; Oncodetect®, a tumor-informed molecular residual disease (MRD) test to help identify cancer recurrence and guide follow-up care; and Cancerguard®, a multi-cancer early detection blood test..

Abbott现在拥有一个全面的产品组合和差异化的产品线，专注于癌症的早期检测和支持个性化治疗。这包括Cologuard®测试，一种市场领先的非侵入性结直肠癌筛查选项；Oncotype DX®，为早期乳腺癌患者提供个性化治疗决策的信息；Oncodetect®，一种基于肿瘤信息的分子残留病（MRD）测试，有助于识别癌症复发并指导后续护理；以及Cancerguard®，一种多癌症早期检测血液测试。

Abbott also adds a leading pipeline of next-generation cancer screening and diagnostics designed to detect cancer even earlier, optimize treatment decisions and enable regular monitoring to help people stay healthy and better manage the disease.

Abbott还增加了一条领先的下一代癌症筛查和诊断管道，旨在更早地检测癌症、优化治疗决策并实现定期监测，以帮助人们保持健康并更好地管理疾病。

About Abbott

关于Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Abbott是一家全球医疗保健领域的领导者，致力于帮助人们在生命的各个阶段更充实地生活。我们改变生命的技术组合涵盖了整个医疗保健领域，在诊断、医疗器械、营养品和品牌仿制药方面拥有领先的业务和产品。我们的122,000名员工为超过160个国家的人们提供服务。

Connect with us at .

通过以下方式与我们联系。

abbott.com

雅培官网

and on

并且继续

LinkedIn

领英

,

，

Facebook

脸书

,

，

Instagram

Instagram

,

，

X

X

and

和

YouTube

YouTube

.

。

Forward-Looking Statements

前瞻性声明

This communication contains forward-looking statements about, among other things, the acquisition of Exact Sciences by Abbott. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

本通讯包含关于Abbott收购Exact Sciences等事项的前瞻性声明。前瞻性声明涉及重大风险和不确定性，可能导致实际结果与这些声明所表达或暗示的内容存在重大差异。

Such risks and uncertainties include, among others, the following: the ability of Abbott to successfully integrate Exact Sciences' operations; the ability of Abbott to implement its plans, forecasts and other expectations with respect to Exact Sciences' business after the completion of the transaction; and risks related to the ability of Abbott to realize the anticipated synergies and benefits of the transaction, including the possibility that the expected synergies and benefits from the transaction will not be realized or will not be realized within the expected time period..

此类风险和不确定性包括但不限于以下方面：Abbott成功整合Exact Sciences运营的能力；Abbott在交易完成后实施其对Exact Sciences业务的计划、预测及其他预期的能力；以及与Abbott实现该交易预期协同效应和利益相关风险，包括可能无法实现交易的预期协同效应和利益，或无法在预期时间内实现的风险。

You should carefully consider the foregoing factors and the other risks and uncertainties that affect the businesses of Abbott and Exact Sciences described in the 'Risk Factors' section in each of Abbott's Annual Report on Form 10- K for the year ended

您应当仔细考虑前述因素以及影响雅培和Exact Sciences业务的其他风险和不确定性，这些内容在雅培年度报告Form 10-K中的“风险因素”部分有所描述。

December 31, 2025

2025年12月31日

, and Exact Sciences' Annual Report on Form 10-K for the year ended

，以及Exact Sciences年度报告表格10-K截止至

December 31, 2025

2025年12月31日

, respectively, and their respective other reports filed with the SEC. Free copies of these documents may be obtained from the SEC's website at

，分别地，以及它们各自向美国证券交易委员会（SEC）提交的其他报告。这些文件的免费副本可以从美国证券交易委员会（SEC）的网站获取，网址为

www.sec.gov

www.sec.gov

. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Abbott undertakes no obligation, and does not intend, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments or otherwise, except as required by law..

前瞻性声明仅在其发布之日有效。读者应注意不要过度依赖前瞻性声明，除非法律要求，否则Abbott没有义务也不打算公开发布因后续事件或发展或其他原因而对前瞻性声明进行的任何修订。

SOURCE Abbott

来源：雅培